THURSDAY, NOVEMBER 23, 2017

Stanford University researchers detail cellular marker discovery

Researchers at Stanford University have discovered a set of cellular markers that distinguish between patients with types of viral infections and those with types of bacterial infections. Read More »

Vaxart enlists subjects for influenza B tablet vaccine trial

Vaxart Inc., a clinical-stage, privately held biotechnology company that creates oral recombinant vaccines in the form of tablets instead of injections, recently enrolled its first subject in the company’s Phase I human trial for the influenza B tablet vaccine. Read More »

California officials say flu vaccine is part of holiday health

California Department of Public Health (CDPH) officials recently stated that the influenza vaccine may be one of the best ways to stay healthy throughout the upcoming holiday season. Read More »

FDA gives priority status to PaxVax's cholera vaccine

The U.S. Food and Drug Administration (FDA) recently gave a priority review status to a Biologics License Application for filing and reviewing a single-dose oral cholera vaccine known as Vaxchora. Read More »

Cepheid's Xpert Flu+RSV Xpress test gains FDA waiver

Cepheid recently gained a Clinical Laboratory Improvement Amendments (CLIA) waiver from the Food and Drug Administration (FDA) for the company’s Xpert Flu+RSV Xpress test. Read More »

Cerberus Capital invests $105 million in PaxVax

Cerberus Capital Management recently invested $105 million in PaxVax Inc., a fully integrated specialty vaccine company that prioritizes creating, producing and selling novel vaccines. Read More »

Mass drug administration credited with stopping malaria in Greece

A mass drug administration (MDA) program has been credited with preventing malaria from spreading throughout Greece, which experienced a resurgence in 2011. Read More »

California reports flu season's first infant death

The California Department of Public Health (CDPH) has confirmed its first flu death involving an infant for the current flu season. Read More »

Researchers make progress in eradicating HIV reservoirs

Researchers recently published a study in PLOS Pathogens showing the significant progress that has been made in growing closer to entirely eliminating HIV reservoirs from patients. Read More »

Report shows countless birds dying from West Nile virus

Researchers from the University of California Los Angeles and other universities recently reported that millions of birds have died because of West Nile virus. Read More »

New vaccine provides full protection against malaria

Aduro Biotech Inc. and Protein Potential LLC recently announced that representatives will present details with pre-clinical data about a new vaccine that offers 100 percent protection against malaria in models. Read More »

Vaxart presents at Vaccine & ISV Congress in Seoul

Vaxart Inc., a privately held, clinical-stage biotechnology company that creates oral recombinant vaccines in the form of tablets instead of injections, had its representatives present details about its oral norovirus and seasonal influenza vaccines this week at the Ninth Vaccine & International Society of Vaccines Congress in Seoul. Read More »

Vaxart to present influenza tablet vaccine data

Vaxart Inc., a privately held clinical-stage biotechnology company that creates oral recombinant vaccines in the form of tablets instead of injections, recently announced that its representatives will present data from its phase 1 study. Read More »

WCCT Global studies H1N1 in California

WCCT Global, a contract research organization based in Orange County, California, recently presented results from its influenza clinical study concerning H1N1 influenza virus at the 2015 Annual ICAAC meeting. Read More »

Study endorses safety of two measles vaccines

A study that lasted for 12 years recently confirmed the overall safety of two vaccines that contain measles strains, stating that the seven major adverse outcomes are not likely for either of the vaccines. Read More »

Ebola drug ZMapp gains fast-track status from the FDA

LeafBio Inc.,  the commercial arm of Mapp Biopharmaceutical Inc., recently announced that its ZMapp has gained fast-track status designation from the U.S. Food and Drug Administration (FDA) as a potential treatment for Ebola. Read More »

Romidepsin shown to reverse HIV latency in some patients

Recent clinical trials found a histone deacetylases (HDAC) inhibitor can be used to eliminate latent HIV virus from its reservoirs throughout the body. Read More »

Calif. tells health care providers to be on the lookout for measles

Warning comes after earlier outbreak that started at Disneyland. Read More »

UCSD School of Medicine researchers report on drug-resistant TB testing

Scientists from the University of California San Diego School of Medicine recently documented three new tests and their accuracy in rapidly diagnosing drug-resistant strains of tuberculosis (TB). Read More »

Vaxart works to advance oral tablet vaccines

Vaxart Inc. is creating a broad range of vaccines that are designed to be taken orally in tablet form rather than by a needle. Read More »